PT MEDIKALOKA HERMINA TBK |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,340 IDR | +0.37% |
|
-1.47% | -10.07% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 10,643,340 | 10,459,390 | 15,701,180 | 22,417,924 | 21,692,778 | 19,952,640 | - | - |
| Enterprise Value (EV) 2 | 11,345 | 11,152 | 16,078 | 23,380 | 23,098 | 21,471 | 20,906 | 20,931 |
| P/E ratio | 42.3 x | 22.6 x | 15.9 x | 75.4 x | 50.1 x | 31.3 x | 27 x | 21.6 x |
| Yield | - | 0.71% | 0.56% | 0.57% | - | 0.68% | 1% | 1.03% |
| Capitalization / Revenue | 2.93 x | 2.37 x | 2.7 x | 4.57 x | 3.75 x | 2.98 x | 2.68 x | 2.34 x |
| EV / Revenue | 3.12 x | 2.53 x | 2.76 x | 4.77 x | 3.99 x | 3.2 x | 2.81 x | 2.45 x |
| EV / EBITDA | 13.1 x | 8.04 x | 7.26 x | 20.5 x | 15.8 x | 11.2 x | 9.68 x | 8.35 x |
| EV / FCF | -3,374 x | 23.9 x | 25 x | -89.5 x | -85 x | -90.5 x | 73.8 x | 43.8 x |
| FCF Yield | -0.03% | 4.19% | 4% | -1.12% | -1.18% | -1.11% | 1.36% | 2.28% |
| Price to Book | 4.96 x | 4.09 x | 4.87 x | 6.52 x | 5.61 x | 4.53 x | 4.04 x | 3.57 x |
| Nbr of stocks (in thousands) | 14,865,000 | 14,815,000 | 14,674,000 | 14,463,176 | 14,558,911 | 14,890,030 | - | - |
| Reference price 3 | 716.0 | 706.0 | 1,070 | 1,550 | 1,490 | 1,340 | 1,340 | 1,340 |
| Announcement Date | 4/5/20 | 5/17/21 | 3/31/22 | 3/31/23 | 3/28/24 | - | - | - |
1IDR in Million2IDR in Billions3IDR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3,631 | 4,416 | 5,820 | 4,902 | 5,784 | 6,704 | 7,432 | 8,532 |
| EBITDA 1 | 866.6 | 1,387 | 2,213 | 1,142 | 1,464 | 1,922 | 2,160 | 2,507 |
| EBIT 1 | 583.3 | 1,042 | 1,778 | 587.4 | 818 | 1,072 | 1,286 | 1,492 |
| Operating Margin | 16.06% | 23.59% | 30.55% | 11.98% | 14.14% | 15.99% | 17.3% | 17.49% |
| Earnings before Tax (EBT) 1 | 505.5 | 946 | 1,658 | 480.1 | 710.4 | 992.9 | 1,176 | 1,470 |
| Net income 1 | 255.4 | 473.2 | 1,003 | 298.6 | 437.3 | 629 | 730.8 | 910 |
| Net margin | 7.03% | 10.72% | 17.24% | 6.09% | 7.56% | 9.38% | 9.83% | 10.67% |
| EPS 2 | 16.92 | 31.18 | 67.28 | 20.57 | 29.73 | 42.85 | 49.72 | 62.17 |
| Free Cash Flow 3 | -3,362 | 466,723 | 642,792 | -261,272 | -271,707 | -237,333 | 283,333 | 478,000 |
| FCF margin | -92.59% | 10,568.81% | 11,044.3% | -5,330.11% | -4,697.49% | -3,540.14% | 3,812.44% | 5,602.19% |
| FCF Conversion (EBITDA) | - | 33,649.82% | 29,040.59% | - | - | - | 13,114.63% | 19,069.37% |
| FCF Conversion (Net income) | - | 98,626.65% | 64,078.89% | - | - | - | 38,770.3% | 52,527.47% |
| Dividend per Share 2 | - | 5.000 | 6.000 | 8.874 | - | 9.152 | 13.40 | 13.79 |
| Announcement Date | 4/5/20 | 5/17/21 | 3/31/22 | 3/31/23 | 3/28/24 | - | - | - |
1IDR in Billions2IDR3IDR in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2023 Q1 | 2023 Q3 | 2023 Q4 | 2024 Q1 |
|---|---|---|---|---|---|
| Net sales 1 | 1,193 | - | 1,538 | 1,554 | 1,706 |
| EBITDA | 469.1 | - | - | - | - |
| EBIT | 358.7 | - | - | 178.6 | - |
| Operating Margin | 30.07% | - | - | 11.49% | - |
| Earnings before Tax (EBT) | 327.7 | - | - | 150.2 | - |
| Net income 1 | 230 | 108.9 | - | 88.51 | 190.9 |
| Net margin | 19.28% | - | - | 5.69% | 11.19% |
| EPS | - | 7.490 | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/31/22 | 4/25/23 | 10/18/23 | 3/28/24 | 4/26/24 |
1IDR in Billions
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 701 | 692 | 376 | 962 | 1,405 | 1,518 | 953 | 979 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 0.8094 x | 0.4992 x | 0.17 x | 0.8426 x | 0.9599 x | 0.79 x | 0.4412 x | 0.3905 x |
| Free Cash Flow 2 | -3,362 | 466,723 | 642,792 | -261,272 | -271,707 | -237,333 | 283,333 | 478,000 |
| ROE (net income / shareholders' equity) | 12.7% | 20.1% | 34.5% | 8.1% | 12% | 14.2% | 15.8% | 16.8% |
| ROA (Net income/ Total Assets) | 5.54% | 8.3% | 14.4% | 5% | 5.34% | 7.04% | 8.17% | 8.93% |
| Assets 1 | 4,610 | 5,702 | 6,971 | 5,972 | 8,197 | 8,935 | 8,949 | 10,187 |
| Book Value Per Share 3 | 144.0 | 172.0 | 220.0 | 238.0 | 266.0 | 296.0 | 332.0 | 375.0 |
| Cash Flow per Share 3 | 37.90 | 74.20 | 125.0 | 59.80 | 89.70 | 93.60 | 107.0 | 123.0 |
| Capex 1 | 576 | 890 | 1,214 | 1,129 | 1,591 | 1,667 | 1,294 | 1,464 |
| Capex / Sales | 15.86% | 20.15% | 20.85% | 23.03% | 27.51% | 24.86% | 17.4% | 17.16% |
| Announcement Date | 4/5/20 | 5/17/21 | 3/31/22 | 3/31/23 | 3/28/24 | - | - | - |
1IDR in Billions2IDR in Million3IDR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
1,340
IDR
Average target price
1,711
IDR
Spread / Average Target
+27.71%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.07% | 1.25B | |
| +19.33% | 84.56B | |
| -26.94% | 72.41B | |
| +2.04% | 27.73B | |
| -8.11% | 17.75B | |
| -1.14% | 17.11B | |
| +5.32% | 16.03B | |
| +71.65% | 13.07B | |
| +6.66% | 12.91B | |
| +71.23% | 12.55B |
- Stock Market
- Equities
- HEAL Stock
- Financials PT Medikaloka Hermina Tbk
